Exemestane vs Modafinil
FDA Approved vs FDA Approved
avoid Mechanism-based · 75% Both Exemestane and Modafinil carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.
Molecular Data
Exemestane Modafinil
Weight 296.40 Da 273.35 Da
Half-life ~24 hours ~12-15 hours
Type Steroidal aromatase inhibitor (irreversible, suicide inhibitor) Diphenylmethylsulfinylacetamide (C15H15NO2S)
Key Benefits
Exemestane
01 Irreversible aromatase inactivation eliminates estrogen rebound upon discontinuation
02 Steroidal structure with mild androgenic activity may offset some low-estrogen side effects
03 Potent estrogen suppression (85-95% reduction in estradiol at full dose)
04 Compatible with tamoxifen (unlike anastrozole, no pharmacokinetic interference)
05 Prevents gynecomastia during testosterone or aromatizable steroid cycles
06 Reduces estrogen-driven water retention, bloating, and blood pressure elevation
07 Oral dosing with once-daily or less frequent administration for cycle support
Modafinil
01 Sustained wakefulness and alertness for 10-15 hours without the jitteriness of traditional stimulants
02 Enhanced executive function, working memory, and decision-making under fatigue
03 Improved focus and concentration during prolonged cognitive tasks
04 Reduced impulsivity and improved task completion in sleep-deprived individuals
05 Low abuse potential relative to amphetamine-class stimulants (Schedule IV)
06 Minimal impact on normal sleep architecture when taken in the morning
Side Effects
Exemestane
Joint pain and stiffness (generally less severe than with anastrozole due to mild androgenic activity)
Fatigue and general malaise
Hot flashes or flushing
Mood changes (irritability, flat affect, low mood)
Headache
Increased sweating
Modafinil
Headache (most frequently reported side effect, often dose-dependent)
Insomnia (particularly if taken too late in the day)
Anxiety and nervousness
Appetite suppression and mild nausea
Dry mouth
Dizziness
Gastrointestinal discomfort (diarrhea, abdominal pain)
Contraindications
Known hypersensitivity to exemestane or any excipients
Premenopausal women (not indicated and potentially harmful to reproductive function)
Pregnancy or breastfeeding (teratogenic risk)
Severe hepatic impairment
Pre-existing severe osteoporosis or high fracture risk
Concurrent use with other aromatase inhibitors (anastrozole, letrozole)
Known hypersensitivity to modafinil or armodafinil
History of Stevens-Johnson Syndrome, TEN, or DRESS with prior modafinil/armodafinil use
Severe hepatic impairment (dose reduction required in moderate impairment)
Unstable angina or recent myocardial infarction
Left ventricular hypertrophy or clinically significant mitral valve prolapse with prior stimulant use
Pregnancy (limited human data; animal studies show teratogenicity at high doses)
Research Evidence
Exemestane Modafinil
Status FDA Approved FDA Approved
References 5 studies 5 studies
FDA Approved Yes Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.